Quinazoline derivatives

Details Quinazoline derivatives Quinazoline derivatives

1996-04-26

1998-06-23

Grumbling, Matthew V.

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Heterocyclic carbon compounds containing a hetero ring...

5142345, 514253, 514259, 544 61, 544119, 544284, 544293, A61K40302, A61K40304, C07D 31535, C07D 3154

Patent

active

057705992

ABSTRACT:
The invention concerns quinazoline derivatives of the formula I ##STR1## wherein n is 1, 2 or 3 and each R.sup.2 is independently halogeno, trifluoromethyl or (1-4C)alkyl;

REFERENCES:
patent: 3266990 (1966-08-01), Lutz et al.
patent: 4343940 (1982-08-01), Kreighbaum et al.
patent: 5457105 (1995-10-01), Barker
patent: 5475001 (1995-12-01), Barker
patent: 5580870 (1996-12-01), Barker et al.
Fry et al., A Specific Inhibitor of the Epidermal Growth Factor Receptor Tyrosine Kinase, Science, Aug. 19, 1994, pp. 1093-1095.
Buchdunger et al., 4,5-Dianilinophthalimide: A protein-tyrosine kinase inhibitor with selectivity for the epidermal growth factor receptor signal transduction pathway and potent in vivo antitumor activity, Proc. Nat. Acad. Sci., 1994, pp. 2334-2338.
Trinks et al., Dianilinophthalimides: Potent and Selective, ATP-Competitive Inhibitors of the EGF-Receptor Protein Tyrosine Kinase, J. Med. Chem., 1994, pp. 1015-1027.
McGuire et al., A new Series of PDGF Receptor Tyrosine Kinase Inhibitors: 3-Substituted Quinoline Derivatives, J. Med. Chem., 1994, pp. 2129-2137.
Dolle et al., 5,7-Dimethoxy-3-(4-pyridinyl)quinoline Is a Potent and Selective Inhibitor of Human Vascular .beta.-Type Platelet-Derived Growth Factor Receptor Tyrosine Kinase, J. Med. Chem., 1994, pp. 2627-2629.
Traxler et al., Recent advances in protein tyrosine kinase inhibitors, Drugs of the Future, 1995, pp. 1261-1274.
Ward et al., Epidermal Growth Factor Receptor Tyrosine Kinase Investigation of Catalytic Mechanism, Structure-Based Searching and Discovery of a Potent Inhibitor, Biochem. Pharmacol., 1994, pp. 659-666.
Rewcastle et al., Tyronsine Kinase Inhibitors. 5.Synthesis and Structure-Activity Relationships . . . Domain of the Epidermal Growth Factor Receptor, J. Med. Chem., 1995, pp. 3482-3487.
Burke, Protein-tyrosine kinase inhibitors, Drugs of the Future, 1992, pp. 119-131.
Spence, Inhibitors of Tyrosine Kinase Activity as Anticancer Therapeutics: Recent Developments, Expert Opin. Therap. Patents, 1993, pp. 3-9.
Spada et al., Small molecule inhibitors of tyrosine kinase activity, Expert Opin. Therap. Patents, 1995, pp. 805-817.
Bridges, The current status of tyrosine kinase inhibitors: do the diarylamine inhibitors of the EGF receptor represent a new beginning?, Expert Opin. Therap. Patents, 1995, pp. 1245-1257.
Iyer et al., Studies in Potential Amoebicides: Part III-Synthesis of 4-Substituted Amino-8-Hydroxy (& 8-Methoxy) Quinazolines & 3-Substituted 8-Hydroxy(&8-Methoxy)-4-Quinazolones, J. Sci. Industr. Res., 1956, pp. 1-7.
Li et al., Chemical Abstracts, 76445u, 1980, p. 674.
Lin et al, Chemical Abstracts, 122728w, 1982, p. 122731.
Bridges, et al., "Enantioselective Inhibition of the Epidermal Growth Factor Receptor Tyrosine Kinase by 4-(.alpha.-Phenethylamino)quinazolines," Bioorganic & Medicinal Chemistry, vol. 3, No. 12, pp. 1651-1656, 1995.

Affiliated with

Also associated with

Rating

Quinazoline derivatives does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Quinazoline derivatives, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Quinazoline derivatives will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-1394986